Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThr

Obiettivo

We have developed the RECOFIB platform, a market first recombinant production platform for human fibrinogen (rhFib) & thrombin (rhThr). Using Chinese Hamster Ovary Cells (CHO) expression technology & patented upstream purification processes, we are the first producer of fully intact & functional recombinant fibrinogen and active thrombin at commercially acceptable cost ending reliance on blood plasma.

Our RECOFIB platform can produce individual fibrinogen variants whose specific functional properties can now be fully harnessed-a breakthrough discovery. From these individual variants, we can develop customized products for [1] bioactive topical hemostats to stop excessive bleeding during surgery; [2] medical implant coating reducing antibiotic resistance of MRSA bacterial biofilms and [3] supply of rhFib variants & rhThr as OEM products. Additional benefits of our rhFib variants compared to plasma fibrinogen include more stability, 10–100X higher purity, and improved safety profile.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2021-ACCELERATOROPEN-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

FIBRIANT BV
Contributo netto dell'UE
€ 2 500 000,00
Indirizzo
EMMY NOETHERWEG 2C
2333 BK LEIDEN
Paesi Bassi
PMI
Sì
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 4 495 826,25